Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele

Clinica Chimica Acta

Volumn 428, Issue , 2014, Pages 77-81

  Hwang, In Cheol ^a   Park, Ji Young ^b   Ahn, Hong Yup ^c   Kim, Kyoung Kon ^a   Suh, Heuy Sun ^a   Ko, Ki Dong ^a   Kim, Kyoung Ah ^b  

^a Gachon University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Dongguk University   (South Korea)

Author keywords

CYP2B6; Polymorphisms; Sibutramine

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; CYCLOBUTANE DERIVATIVE; CYP2B6 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; LACTONE;

ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; CYP2B6 GENE; CYP2C19 GENE; CYP3A5 GENE; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ADOLESCENT; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GENETICS; HEART RATE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; CYCLOBUTANES; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEART RATE; HUMANS; LACTONES; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PULSE; REGRESSION ANALYSIS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84888154049     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.007     Document Type: Article

References (34)

1. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999, 23:1016-1024.
2. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998, 6(Suppl. 2):51S-209S.
3. Heal D.J., Aspley S., Prow M.R., Jackson H.C., Martin K.F., Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998, 22(Suppl. 1):S18-28. [discussion S29].
4. Luscombe G.P., Hopcroft R.H., Thomas P.C., Buckett W.R. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989, 28:129-134.
5. McNeely W., Goa K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998, 56:1093-1124.
6. Bae S.K., Cao S., Seo K.A., et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos 2008, 36:1679-1688.
7. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007, 116:496-526.
8. Chung J.Y., Jang S.B., Lee Y.J., Park M.S., Park K. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2011, 51:53-59.
9. Kim K.A., Song W.K., Park J.Y. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009, 86:511-518.
10. Tomalik-Scharte D., Lazar A., Fuhr U., Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008, 8:4-15.
11. Brownell K.D. The LEARN manual for weight management 2004, American Health Publishing Company, Dallas. 10 ed.
12. Delahanty L.M., Peyrot M., Shrader P.J., Williamson D.A., Meigs J.B., Nathan D.M. Pretreatment, psychological, and behavioral predictors of weight outcomes among lifestyle intervention participants in the Diabetes Prevention Program (DPP). Diabetes Care 2013, 36:34-40.
13. Xu C., Qi S., Gao L., et al. Genetic polymorphisms of LMP/TAP gene and hepatitis B virus infection risk in the Chinese population. J Clin Immunol 2007, 27:534-541.
14. James W.P., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119-2125.
15. Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167-172.
16. Benedetti F., Dallaspezia S., Colombo C., Lorenzi C., Pirovano A., Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 2010, 25:476-478.
17. Turpeinen M., Tolonen A., Uusitalo J., Jalonen J., Pelkonen O., Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005, 77:553-559.
18. Bae J.W., Jang C.G., Lee S.Y. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 2011, 51:1704-1711.
19. James W.P., Caterson I.D., Coutinho W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363:905-917.
20. Marmot M.G., Elliott P. Coronary heart disease epidemiology: from aetiology to public health 2005, Oxford University Press, Oxford. 2nd ed.
21. Heusser K., Tank J., Diedrich A., et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006, 79:500-508.
22. Hanotin C., Thomas F., Jones S.P., Leutenegger E., Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998, 22:32-38.
23. Zannad F., Gille B., Grentzinger A., et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002, 144:508-515.
24. Jordan J., Scholze J., Matiba B., Wirth A., Hauner H., Sharma A.M. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005, 29:509-516.
25. Cook S., Togni M., Schaub M.C., Wenaweser P., Hess O.M. High heart rate: a cardiovascular risk factor?. Eur Heart J 2006, 27:2387-2393.
26. Stock M.J. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997, 21(Suppl. 1):S25-S29.
27. Kim K.S., Kim E.J., Lee H.A., Park S.J. Effect of sibutramine HCl on cardiac hERG K+ channel. Mol Cell Biochem 2009, 320:125-131.
28. Hofmann M.H., Blievernicht J.K., Klein K., et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008, 325:284-292.
29. Zanger U.M., Klein K., Saussele T., Blievernicht J., Hofmann M.H., Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007, 8:743-759.
30. Telenti A., Zanger U.M. Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 2008, 48:227-256.
31. Totah R.A., Sheffels P., Roberts T., Whittington D., Thummel K., Kharasch E.D. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008, 108:363-374.
32. Elfhag K., Finer N., Rossner S. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes Obes Metab 2008, 10:498-505.
33. LeBlanc M., Thibault L. Effect of sibutramine on macronutrient selection in male and female rats. Physiol Behav 2003, 80:243-252.
34. Foltin R.W. Effects of sibutramine on the appetitive and consummatory aspects of feeding in non-human primates. Physiol Behav 2006, 87:280-286.